Gerresheimer's Liquidity Race Against a Regulatory Clock

Gerresheimer scrambles for cash, selling its Centor unit to avoid default after accounting errors delay audits, triggering SDAX expulsion and a 68% stock plunge.

The immediate fallout from Gerresheimer's accounting crisis is a scramble for cash. To stave off a technical default on its credit lines, the packaging group has hired Morgan Stanley to sell its US subsidiary Centor. The business, specializing in medicine packaging, was valued at 292 million euros at the end of 2024 and is slated to change hands this year. This urgent divestment runs parallel to the company's negotiations with banks for extensions on its loan agreements, aiming to prevent a full-blown covenant breach.

These drastic measures follow a chain reaction triggered by the absence of audited financial statements. Because its certified annual and group financial report for 2024/2025 was not filed by the legal deadline of March 31, Gerresheimer will be formally ejected from the SDAX index on April 10, 2026. The delay breaches the basic criteria of the DAX index methodology, handing the index slot to Bulgarian smart-home specialist Shelly Group SE.

The root of the problem lies deeper than a missed date. Germany's financial watchdog, BaFin, has accused the company of specific accounting errors requiring an in-depth audit. A second auditing firm, Grant Thornton, is now examining the books amid suspicions of faulty lease accounting and omitted impairments. The previously undisputed 2024 annual report contained flawed bookings of 35 million euros from impermissible "bill-and-hold" arrangements. Audited figures are not expected before June 2026.

This regulatory limbo has frozen the company's financial calendar. The quarterly statement for Q1 2026 has been postponed, and the Annual General Meeting originally scheduled for June 3 cannot proceed. The crisis has also ensnared its former auditor and executives. The auditor oversight body APAS has initiated a professional misconduct procedure against KPMG for issuing an unqualified audit opinion on the flawed 2024 accounts. Simultaneously, shareholder association DSW is examining damage claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, linked to anticipated write-downs of up to 240 million euros on projects from the acquired Sensile Medical and a glass plant in Chicago slated for closure.

The SDAX expulsion creates a tangible technical overhang on the stock. Institutional investors whose mandates are tied to index membership face forced selling obligations. This adds pressure to a share price that has already plummeted approximately 68.42% over the past twelve months, trading nearly 73% below its 52-week high.

Despite the unresolved issues, some institutional buyers are seeing value at depressed levels. Asset managers including Deka Investment and CastleKnight have recently reported new stakes. All strategic and financial decisions now converge on June 2026. By then, management must present the delayed and certified 2025 annual report. This deadline is the essential prerequisite for permanently securing credit lines, substantiating a revenue forecast of up to 2.4 billion euros for the current year, and restarting the blocked financial calendar.